Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Mild Cognitive ImpairmentProdromal Alzheimer's Disease
Interventions
DRUG

Placebo Oral Tablet

Placebo oral tablet

DRUG

AGB101 220 mg tablet

220 mg AGB101 active compound

Trial Locations (24)

10312

Richmond Behavioral Associates, Staten Island

12208

Neurological Associates of Albany PC, Albany

21205

Johns Hopkins University School of Medicine, Baltimore

29401

Clinical Biotechnology Research Institute at RSFH, Charleston

30033

NeuroStudies.net, LLC, Decatur

32806

Bioclinica Research, Orlando

33009

MD Clinical, Hallandale

33137

Miami Jewish Health, Miami

33157

IMIC Research, Palmetto Bay

33437

Boynton Beach Medical Research Institite, Boynton Beach

33445

Brain Matters Research, Delray Beach

34243

The Roskamp Institute, Inc, Sarasota

34997

Brain Matters Research, Stuart

39401

Memory Center/Hattiesburg Clinic, Hattiesburg

60640

Great Lakes Clinical Trials, Chicago

63005

Clinical Research Professionals, Chesterfield

80218

The Mile High Research Center, Denver

85006

Banner Alzheimer's Institute, Phoenix

92056

Excell Research Inc, Oceanside

92653

Senior Clinical Trials, Inc., Laguna Hills

07856

The NeuroCognitive Institute, Mount Arlington

08540

Global Medical Institutes LLC; Princeton Medical Institute, Princeton

07764

Neurology Specialist of Monmouth County, PA, West Long Branch

M3B 2S7

Toronto Memory Program, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

AgeneBio

INDUSTRY

NCT03486938 - Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter